Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia

Georgina L. Ryland; Allison Barraclough; Chun Yew Fong; Shaun Fleming; Ashish Bajel; Oliver Hofmann; David Westerman; Sean Grimmond; Piers Blombery

doi:10.1111/bjh.16949

Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia

Georgina L. Ryland, Allison Barraclough, Chun Yew Fong, Shaun Fleming, Ashish Bajel, Oliver Hofmann, David Westerman, Sean Grimmond, Piers Blombery

Research output: Contribution to journal › Letter › Other › peer-review

6 Citations (Scopus)

Original language	English
Pages (from-to)	123-126
Number of pages	4
Journal	British Journal of Haematology
Volume	191
Issue number	1
DOIs	https://doi.org/10.1111/bjh.16949
Publication status	Published - 1 Oct 2020
Externally published	Yes

Access to Document

10.1111/bjh.16949

Cite this

@article{f6516db1c95149afa3e3784834b01d1f,

title = "Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia",

author = "Ryland, {Georgina L.} and Allison Barraclough and Fong, {Chun Yew} and Shaun Fleming and Ashish Bajel and Oliver Hofmann and David Westerman and Sean Grimmond and Piers Blombery",

note = "Funding Information: Allison Barraclough has received travel support from Roche; Chun Yew Fong has served on the Speakers{\textquoteright} Bureau for Amgen and Pfizer and has served on the Scientific Advisory Board for Amgen and Pfizer. Chun Yew Fong has received research funding from Amgen unrelated to the current manuscript. All other authors declare no competing financial interests. Funding Information: This work was supported by grants from the Wilson Centre for Lymphoma Genomics and the Snowdome Foundation. ",

year = "2020",

month = oct,

day = "1",

doi = "10.1111/bjh.16949",

language = "English",

volume = "191",

pages = "123--126",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia

AU - Ryland, Georgina L.

AU - Barraclough, Allison

AU - Fong, Chun Yew

AU - Fleming, Shaun

AU - Bajel, Ashish

AU - Hofmann, Oliver

AU - Westerman, David

AU - Grimmond, Sean

AU - Blombery, Piers

N1 - Funding Information: Allison Barraclough has received travel support from Roche; Chun Yew Fong has served on the Speakers’ Bureau for Amgen and Pfizer and has served on the Scientific Advisory Board for Amgen and Pfizer. Chun Yew Fong has received research funding from Amgen unrelated to the current manuscript. All other authors declare no competing financial interests. Funding Information: This work was supported by grants from the Wilson Centre for Lymphoma Genomics and the Snowdome Foundation.

PY - 2020/10/1

Y1 - 2020/10/1

UR - http://www.scopus.com/inward/record.url?scp=85087681668&partnerID=8YFLogxK

U2 - 10.1111/bjh.16949

DO - 10.1111/bjh.16949

M3 - Letter

C2 - 32648276

AN - SCOPUS:85087681668

SN - 0007-1048

VL - 191

SP - 123

EP - 126

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia

Access to Document

Other files and links

Cite this